Biotech News
Related news
NTLAIntellia2026-08-06 11:00 EST
Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates
NTLAIntellia2026-05-11 11:30 EST
Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates
OCGNOcugen2026-07-28 20:01 EST
Ocugen to Host Conference Call on Thursday, August 6 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2026 Financial Results
ABEOAbeona Therapeutics2026-08-06 11:30 EST
Abeona Therapeutics® to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026
OCGNOcugen2026-04-29 11:02 EST
Ocugen to Host Conference Call on Tuesday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2026 Financial Results
SRPTSarepta Therapeutics2026-08-05 20:05 EST
Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments
CRSPCRISPR Therapeutics2026-08-03 20:15 EST
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results
TSHATaysha Gene Therapies2026-08-04 20:00 EST
Taysha Gene Therapies to Release Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 11
SRPTSarepta Therapeutics2026-07-22 12:30 EST
Sarepta Therapeutics to Announce Second Quarter 2026 Financial Results
SGMOSangamo Therapeutics, Inc.2026-05-14 20:01 EST
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2026 Financial Results
Intellia
In Vivo CRISPR Gene Editing Intellia Therapeutics develops potentially one-time medicines using CRISPR-based gene editing. Its lead programs edit disease-causing genes directly inside the body through systemically delivered therapies. Hereditary Angioedema Lonvoguran ziclumeran, or lonvo-z, is an in vivo gene-editing candidate designed...
Recent company news
NTLAIntellia2026-08-07 20:01 EST
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NTLAIntellia2026-08-06 11:00 EST
Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates
NTLAIntellia2026-07-30 12:00 EST
Intellia Therapeutics to Hold Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Business Updates
NTLAIntellia2026-07-06 20:05 EST
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NTLAIntellia2026-06-13 11:30 EST
Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema
Stock data
- Close
- 11.24 USD
- Market cap
- 1.83B USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States